3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
75
Neoplasm Metastasis
12
Neoplasms
8
Ovarian Neoplasms
6
Endometrial Neoplasms
6
Pancreatic Neoplasms
5
Carcinoma, Renal Cell
5
Sarcoma
4
Neoplasms by Site
4
Lymphoma, Non-Hodgkin
4
Breast Diseases
4
Squamous Cell Carcinoma of Head and Neck
3
Multiple Myeloma
3
Lymphoma
3
Lung Neoplasms
3
Liposarcoma
3
Kidney Neoplasms
3
Head and Neck Neoplasms
3
Glioma
3
Wilms Tumor
2
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Recurrence
2
Prostatic Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Interventions
Fluorouracil
9
Oxaliplatin
7
Leucovorin
7
Surveys and Questionnaires
6
Blood Specimen Collection
6
Bevacizumab
6
Specimen Handling
5
Gemcitabine
5
Cetuximab
5
Capecitabine
5
fludarabine
4
aldesleukin
4
Standard of Care
4
Irinotecan
4
Cyclophosphamide
4
Remote Patient Monitoring
3
Radiosurgery
3
Pafolacianine
3
Nivolumab
3
Endoscopic Mucosal Resection
3
Cisplatin
3
130-nm albumin-bound paclitaxel
3
encorafenib
2
Tomography, X-Ray Computed
2
Sunitinib
2
Referral and Consultation
2
Radiotherapy
2
Practice Guidelines as Topic
2
Pemetrexed
2
Magnetic Resonance Spectroscopy
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Neoplasms
×
palbociclib
×
1 year
×
Clear all
NCT05039177
2026-03-25
HERKULES-3
Erasca, Inc.
Phase 1/2
Completed
101 enrolled